565 / 1674
A phase I/II trial in an Asian population
Kawamura M et al, Radiat Oncol 2015
A hypertrophic scar disappeared
by the 3-year follow-up
A hypertrophic scar or keloid
lasting for more than 3 years
Dose escalation study from 19 to 21 Gy
Mobile Linac (Mobetron)
30 patients completed the protocol
50% suitable for ASTRO
No Local Recurrence at 6 years
No Regional or Distant Recurrence
No breast cancer related deaths